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Chronic itch is a debilitating symptom of inﬂammatory skin conditions, such as atopic dermatitis, and
systemic diseases, for which existing treatment is largely ineffective. Recent studies have revealed the
selective neuronal pathways that are involved in itch sensations; however, the mechanisms by which
itch turns into a pathological chronic state are poorly understood. Recent advances in our understanding
of the mechanisms producing chronic itch have been made by deﬁning causal roles for astrocytes in the
spinal dorsal horn in mouse models of chronic itch including atopic dermatitis. Understanding the key
roles of astrocytes may provide us with exciting insights into the mechanisms for itch chronicity and lead
to a previously unrecognized target for treating chronic itch.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Itch (or pruritus) is an unpleasant sensation that elicits the
desire or reﬂex to scratch and normally serves as a self-protection
mechanism from harmful external agents such as parasites.1,2 In
general, scratching can transiently relieve such itching sensations.
However, under pathological conditions such as skin diseases like
atopic dermatitis, other systemic disorders, such as liver and kidney
diseases or HIV/AIDS, as well as metabolic disorders, itch becomes
more severe and chronic, which leads to excessive, repetitive
scratching.1,3e5 Such scratching causes skin lesions, which can
worsen the itch sensation and lead to further scratching (the vi-
cious itchescratch cycle).1,3 Chronic itch affects millions ofof Pharmaceutical Sciences,
ka 812-8582, Japan.
ety of Allergology.
rgology. Production and hosting by Elseindividuals worldwide,6 but identifying the optimal treatment for it
is a major clinical challenge.
A rapidly growing body of literature has revealed the existence
of itch-speciﬁc neuronal circuitry in the peripheral and central
nervous system,1,2,7,8 and it has been proposed that aberrant
modiﬁcation of itch signaling at the levels of primary afferents and
the spinal dorsal horn (SDH) might be involved in pathological
chronic itch. Despite such progress in our understanding of the
neuronal basis for itch sensation, the mechanisms by which itch
turns into a pathological chronic state are poorly understood. In
this review, recent advances in our understanding of the mecha-
nisms that underlie chronic itch are highlighted, with a speciﬁc
focus on the role of astrocytes, a type of glial cell in the central
nervous system (CNS).
Glial cells in the CNS
Rudolph Virchow, a German anatomist, ﬁrst found non-
neuronal cells in the CNS and called them “glia”, the Greek wordvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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become apparent that glia are much more than “glue”, but rather
are active players having crucial roles in controlling neuronal
functions.10,11 Glial cells express a number of neurotransmitter re-
ceptors for receiving inputs from neighboring cells including neu-
rons and also a number of biologically active substances for giving
signals to the cells. Glial cells are mainly classiﬁed into three
groups: astrocytes, oligodendrocytes andmicroglia. The former two
cell-types are derived from neural stem cells,12 whereas microglia
originate from precursor cells in the yolk sac during early embry-
onic development.13,14 In the CNS, astrocytes are themost abundant
population. Based on their morphology and location, rodent as-
trocytes have been classiﬁed into two groups, protoplasmic astro-
cytes in the grey matter and ﬁbrous astrocytes in the white
matter.15 Protoplasmic astrocytes ensheath synapses and are in
contact with blood vessels, and ﬁbrous astrocytes are in contact
with the nodes of Ranvier.15 However, recent studies have indicated
a diverse cell population, with distinct properties in different brain
regions.16,17 Astrocytes occupy nonoverlapping spatial territories,
and their processes are intimately associated with synapses.15,18
The processes of one astrocyte are known to contact tens of thou-
sands of synapses at a structure termed the tripartite synapse to
recognize the structural and functional relationship between the
astrocyte and the pre- and postsynaptic terminals.18,19 Astrocytes
do not produce action potentials, but they do increase intracellular
Ca2þ levels in response to neurotransmitters (glutamate, dopamine,
noradrenalin, serotonin, ATP, etc.) via activation of their cognate
receptors.20,21 By responding to such extracellular stimuli, astro-
cytes evoke various cellular responses including production and
release of gliotransmitters (ATP, D-serine, and glutamate) and tro-
phic factors, which act on neurons and modulate synapse forma-
tion, maturation, efﬁcacy, and plasticity.15,20,22 A growing body ofSpinal dorsal horn
G
Fig. 1. Reactive astrocytes in the spinal dorsal horn in a model of atopic dermatitis. Immun
CV-NC/Nga mice. CV-NC/Nga mice have astrocytes with upregulated GFAP in the SDH. Morp
processes.evidence using astrocyte-speciﬁc molecular and genetic manipu-
lations has revealed that astrocytes play a pivotal role in neuronal
function under physiological and pathological
conditions.15,17,20,22e25Reactive astrocytes in the SDH in models of chronic itch
Advances in the understanding of the mechanisms of acute and
chronic itch have been achieved by the development of animal
models. For chronic itch, several models have been established,
most of which focus on cutaneous skin diseases, including atopic
dermatitis, contact dermatitis and xerosis (dry skin).8,26,27 Using
the model of atopic dermatitis NC/Nga mice, an inbred strain of
Japanese fancy mice that show spontaneous scratching behaviors
when maintained under conventional (CV), but not speciﬁc-
pathogen-free (SPF) conditions,28 it was found that CV-NC/Nga
mice have astrocytes with upregulated glial ﬁbrillary acidic pro-
tein (GFAP), an astrocytic marker, in the SDH (Fig. 1).29 Morpho-
logically, the SDH astrocytes showed enlarged cell bodies and
extensively arborized processes. These alterations are well-known
histological criteria of reactive astrocytes.30 Furthermore, reactive
astrocytes in the SDH have also been reported in models of contact
dermatitis29 and dry skin.31 Thus, reactive astrogliosis in the SDH
occurs under chronic itch conditions.
Interestingly, astrocytic activation seems not to be induced in all
SDH segments. Indeed, reactive astrocytes in the SDH are observed
mainly in cervical and trigeminal segments that correspond to the
nape of neck, rostral back, ear and face where the itchy mice have
extensively scratched and skin lesions have developed.29 In
contrast, in the lumbar segments that do not corresponded with
lesioned skin, GFAP expression is unchanged. Thus, reactive astro-
cytes may be restricted to the segments corresponding to theAstrocytes
SPF-NC/Nga
FAP
CV-NC/Nga
oﬂuorescence of the marker of astrocytes in the cervical spinal dorsal horn of SPF- and
hologically, the SDH astrocytes showed enlarged cell bodies and extensively arborized
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activation might be due to direct damage to a peripheral nerve by
repetitive scratching because primary afferent sensory neurons do
not express activating transcription factor 3 (ATF3),29 a neuronal
injury marker.32
Temporal correlation between reactive astrocytes and
itchescratch cycle
A clinically important element of chronic itch is the vicious cycle
of itching and scratching. In CV-NC/Ngamice, scratching behavior is
induced at the age of 4 weeks, but skin lesions due to scratching are
only observed from approximately 8 weeks of age.29 It is thus
conceivable that the itchescratch cycle might also be established
around this time in CV-NC/Nga mice. Interestingly, GFAP upregu-
lation in the SDH is observed only between the ages of 8 and 15
weeks, much later than 4 weeks.29 Thus it appears that the time
course of the appearance of reactive astrocytes matches that of the
initiation of the itchescratch cycle. Furthermore, preventing
scratch-induced skin damage by trimming the toenails of CV-NC/
Nga mice leads to a recovery from their skin lesions and attenu-
ates GFAP upregulation, as well as reductions in scratching. Similar
results were obtained in a model of contact dermatitis. Further-
more, protecting mice from scratching by using an Elizabethan
collar prevents GFAP upregulation in the SDH.31 Thus, it seems
likely that SDH astrogliosis under chronic itch conditions might be
associated with physical and/or chemical stimulation to the skin by
scratching or inﬂammatory factors.
The mechanism underlying the induction of reactive astrocytes
remains to be determined, but the segment in the SDH receiving
primary afferent neurons connected with the lesion itchy skin
matches that having reactive astrocytes, therefore, astrocytic acti-
vation might require a signal from the skin. Tominaga et al. have
demonstrated that hyperinnervation of primary afferent C-ﬁbers
expressing the transient receptor potential cation channel sub-
family V member 1 (TRPV1) to the epidermis occurs in lesioned
itchy skin of CV-NC/Nga mice.33 In patients with atopic dermatitis,
the density of epidermal nerve ﬁbers is higher in the skin,34,35
suggesting that hyperinnervation might be responsible for
chronic itch. It was found that ablation of TRPV1-positive primary
afferent C-ﬁbers by systemically administering the ultrapotent
TRPV1 agonist resiniferatoxin (RTX)36 suppresses GFAP upregula-
tion.29 Thus, reactive astrocytes under chronic itch conditions
might be maintained by the lesioned skin in a manner that requires
TRPV1þ C-ﬁbers. What biologically active substances are released
from primary afferent terminals in the SDH and activates astrocytes
under chronic itch condition is a major issue for future
investigations.
SDH astrocytes are necessary for chronic itch
Recent studies have implicated SDH reactive astrocytes in
chronic itch by demonstrating that repetitive scratching behaviors
in models of chronic itch requires the transcription factor signal
transducer and activator of transcription 3 (STAT3)29 and the re-
ceptor toll-like receptor 4 (TLR4),31 both of which in the SDH are
selectively activated and expressed in reactive astrocytes.
STAT3 is a member of the STAT family of transcription factors,
which has been implicated in the astrocytic activation30 that ap-
pears required for chronic itch. Evidence implicating STAT3 came
from convergent results of pharmacological and molecular in-
vestigations. It was found that the SDH cells activating STAT3 are
astrocytes and because acute pharmacological inhibition of spinal
cord STAT3 by intrathecal administration of AG490, an inhibitor of
the STAT3 activator Janus kinase (JAK), to the cervical spinalsegments suppresses GFAP upregulation and scratching behaviors
in models of chronic itch.29 It appears that ongoing STAT3 activa-
tion is crucial for maintaining reactive astrocytes and chronic itch.
Moreover, a similar reduction was observed in Gfap-cre:Stat3ﬂox/ﬂox
mice, in which astrocytic STAT3 is inactivated by an astrocyte-
selective Cre recombination. In contrast, these mice have normal,
acute itch responses to histamine and chloroquine (non-hista-
minergic itch). Thus, STAT3-dependent reactive state of astrocytes
in the SDH is necessary for the progression and maintenance of
chronic itch.29
TLR4 has been also reported to be required for chronic itch.31
TLR4 is a member of the TLR family and mediates innate and
adaptive immunity by recognition of exogenous ligands, pathogen-
associated molecular patterns after viral and bacterial infection,
and also detection of endogenous ligands, danger-associated mo-
lecular patterns produced by tissue injury.37 TLR4 and other TLRs
have been reported to be expressed in glial cells in the CNS, and
activation of these receptors produces a variety of proinﬂammatory
mediators such as cytokines and chemokines.38 Liu et al. have
shown that TLR4-knockout mice display reduced spontaneous
scratching and touch-evoked scratching (alloknesis) in chronic itch
models associated with dry skin and contact dermatitis.31 A similar
reduction is observed in mice intrathecally treated with an antag-
onist for TLR4, suggesting an involvement of TLR4 in the spinal
cord. Spinal TLR4 expression is upregulated in chronic itch models
and restricted to astrocytes. Interestingly, TLR4-knockout mice
showed a reduction in the GFAP upregulation observed in chronic
itch models,31 suggesting that TLR4 might play a role in astrocyte
activation in the SDH. In addition, intrathecal treatment with an
astroglial toxin suppressed spontaneous scratching and
alloknesis.31
Thus, the above ﬁndings showing suppression of chronic itch by
inhibiting two distinct types of signaling molecule, STAT329 and
TLR4,31 whose expressionwithin the SDH is restricted to astrocytes
makes a strong case that reactive astrocytes play a causal role in
chronic itch.
Modulation of SDH itch signaling by reactive astrocytes
Given the evidence that the astrocytic molecules, STAT3 and
TLR4, are necessary for chronic itch,29,31 astrocytes must inﬂuence
activity of SDH neurons involved in the itch processing. Indeed,
pharmacological and genetic manipulations of STAT3 decreased
SDH neurons positive for c-Fos,29 a marker of neuronal activity.
Furthermore, CV-NC/Nga mice show an increase in scratching
behavior evoked by intrathecal administration of gastrin-releasing
peptide (GRP),29 which speciﬁcally induces itch by acting on GRP
receptor (GRPR)-expressing SDH neurons,39,40 which, interestingly,
is abolished by intrathecal administration of AG490,29 a regimen
that is effective to suppress reactive astrocytes in the SDH. Thus,
astrocytic STAT3 activation under chronic itch conditions contrib-
utes to enhanced GRP-evoked itch signaling in the SDH.
A major issue is then to determine the mechanism(s) by which
astrocytes promote itch signaling in the SDH. One candidate for
astrocytic factors that modulate itch signaling has been identiﬁed,
speciﬁcally lipocalin-2 (LCN2).29 Several studies have implicated
LCN2 as a protein secreted from reactive astrocytes in response to
neuronal inﬂammation41e43 and in the modulation of neuronal
excitability.44 LCN2 mRNA and protein levels in models of chronic
itch are upregulated and this upregulation is suppressed in Gfap-
cre:Stat3ﬂox/ﬂox mice.29 The localization of LCN2 in the SDH is spe-
ciﬁc to astrocytes. Furthermore, LCN2-knockout mice display a
reduction in scratching, and knockdown of LCN2 by intrathecal
administration of LCN2 siRNA reverses chronic itch. Moreover, the
pivotal role of astrocytic LCN2 has been demonstrated by
Primary afferent 
sensory neurons
(TRPV1+ C-fiber)
Scratching
Dermatitis
Reactive astrocytes
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Fig. 2. Schematic illustration of astrocyte-mediated ampliﬁcation of spinal itch signaling. Under chronic itch conditions, scratching causes skin lesions, which in turn lead to
activation of STAT3 in SDH astrocytes in a manner that requires TRPV1þ C-ﬁbers. Activation of STAT3 and TLR4 causes astrocytes to be reactive. Induction of LCN2 production
involves STAT3. LCN2 then sensitizes an itch processing neuronal network involving GRPRþ SDH neurons. Enhanced itch signaling leads to excessive scratching, worsening skin
lesions, which maintains enhanced astroglial reactivity, and thereby contributes to the vicious cycle of itching and scratching, and to chronic itch.
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encoding an LCN2 shRNA into the parenchyma of the cervical SDH
of CV-NC/Nga mice.29 Intrathecal co-administration of LCN2 with
GRP markedly enhances GRP-evoked scratching. These results
together indicate that LCN2 is an astrocytic factor that plays a
pivotal role in the progression and maintenance of chronic itch.
In addition, a recent study has revealed a neuronal pathway in
the SDH for mechanical itch,46 which is distinct from the pathway
for chemical itch involving GRP-GRPR signaling. From the ﬁnding
showing that inhibiting spinal TLR4 expressed in astrocytes sup-
presses the touch-induced itch alloknesis,31 it is possible that
reactive astrocytes in the SDH may also inﬂuence mechanical itch
signaling through a GRP-GRPR-independent SDH neuronal circuit.Conclusions
This article primarily focused on the role of astrocytes in chronic
itch. A model of the mechanisms underlying astrocytic modulation
of chronic itch in the SDH is presented in Figure 2. Of note, phar-
macological, molecular, and genetic manipulations of the functionor expression of astrocytic STAT3 and TLR4 substantially inﬂuences
chronic itch behaviors and, importantly, have no effect on acute
histaminergic and non-histaminergic itch behaviors under normal
conditions.29,31 Therefore, astrocytic molecules might be a prom-
ising target for treating chronic itch.47 This hypothesis would be
strengthened by providing clinical evidence for the presence of
reactive astrocytes in the SDH of patients with chronic itch such as
atopic dermatitis (which is an important issue in the future)
because in patients with atopic dermatitis, intense itch sensations
appear only in the lesioned skin, which is considered to be medi-
ated by spinal sensitization.48 It is expected that an increased un-
derstanding of the functions of SDH astrocytes will provide us with
exciting insights into the mechanisms for itch chronicity and clues
to develop novel therapeutic agents for treating chronic itch.Acknowledgments
This work was supported by JSPS KAKENHI Grant Numbers
15K15203, and The Uehara Memorial Foundation.
M. Tsuda / Allergology International 66 (2017) 31e35 35Conﬂict of interest
The author has no conﬂict of interest to declare.
References
1. Ikoma A, Steinhoff M, Stander S, Yosipovitch G, Schmelz M. The neurobiology of
itch. Nat Rev Neurosci 2006;7:535e47.
2. LaMotte RH, Dong X, RingkampM. Sensory neurons and circuits mediating itch.
Nat Rev Neurosci 2014;15:19e31.
3. Ikoma A. Updated neurophysiology of itch. Biol Pharm Bull 2013;36:1235e40.
4. Dhand A, Aminoff MJ. The neurology of itch. Brain 2014;137:313e22.
5. Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med
2013;368:1625e34.
6. Miller G. Biomedicine. Grasping for clues to the biology of itch. Science
2007;318:188e9.
7. Han L, Dong X. Itch mechanisms and circuits. Ann Rev Biophys 2014;43:331e55.
8. Bautista DM, Wilson SR, Hoon MA. Why we scratch an itch: the molecules, cells
and circuits of itch. Nat Neurosci 2014;17:175e82.
9. Somjen GG. Nervenkitt: notes on the history of the concept of neuroglia. Glia
1988;1:2e9.
10. Volterra A, Meldolesi J. Astrocytes, from brain glue to communication ele-
ments: the revolution continues. Nat Rev Neurosci 2005;6:626e40.
11. Freeman MR, Rowitch DH. Evolving concepts of gliogenesis: a look way back
and ahead to the next 25 years. Neuron 2013;80:613e23.
12. Rowitch DH, Kriegstein AR. Developmental genetics of vertebrate glial-cell
speciﬁcation. Nature 2010;468:214e22.
13. Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. Origin and differentiation of
microglia. Front Cell Neurosci 2013;7:45.
14. Ransohoff RM, Cardona AE. The myeloid cells of the central nervous system
parenchyma. Nature 2010;468:253e62.
15. Eroglu C, Barres BA. Regulation of synaptic connectivity by glia. Nature
2010;468:223e31.
16. Molofsky AV, Krencik R, Ullian EM, Tsai HH, Deneen B, Richardson WD, et al.
Astrocytes and disease: a neurodevelopmental perspective. Genes Dev
2012;26:891e907.
17. Khakh BS, Sofroniew MV. Diversity of astrocyte functions and phenotypes in
neural circuits. Nat Neurosci 2015;18:942e52.
18. Freeman MR. Speciﬁcation and morphogenesis of astrocytes. Science 2010;330:
774e8.
19. Perea G, Navarrete M, Araque A. Tripartite synapses: astrocytes process and
control synaptic information. Trends Neurosci 2009;32:421e31.
20. Halassa MM, Haydon PG. Integrated brain circuits: astrocytic networks
modulate neuronal activity and behavior. Ann Rev Physiol 2010;72:335e55.
21. Bazargani N, Attwell D. Astrocyte calcium signaling: the third wave. Nat Neu-
rosci 2016;19:182e9.
22. Clarke LE, Barres BA. Emerging roles of astrocytes in neural circuit develop-
ment. Nat Rev Neurosci 2013;14:311e21.
23. Sofroniew MV. Astrocyte barriers to neurotoxic inﬂammation. Nat Rev Neurosci
2015;16:249e63.
24. Robel S, Sontheimer H. Glia as drivers of abnormal neuronal activity. Nat
Neurosci 2016;19:28e33.
25. Ji RR, Berta T, Nedergaard M. Glia and pain: is chronic pain a gliopathy? Pain
2013;154(Suppl. 1):S10e28.
26. Tanaka A, Amagai Y, Oida K, Matsuda H. Recent ﬁndings in mouse models for
human atopic dermatitis. Exp Anim 2012;61:77e84.
27. Kuraishi Y. Methods for preclinical assessment of antipruritic agents and itch
mechanisms independent of mast-cell histamine. Biol Pharm Bull 2015;38:
635e44.28. Matsuda H, Watanabe N, Geba GP, Sperl J, Tsudzuki M, Hiroi J, et al. Devel-
opment of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/
Nga mice. Int Immunol 1997;9:461e6.
29. Shiratori-Hayashi M, Koga K, Tozaki-Saitoh H, Kohro Y, Toyonaga H,
Yamaguchi C, et al. STAT3-dependent reactive astrogliosis in the spinal dorsal
horn underlies chronic itch. Nat Med 2015;21:927e31.
30. Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar for-
mation. Trends Neurosci 2009;32:638e47.
31. Liu T, Han Q, Chen G, Huang Y, Zhao LX, Berta T, et al. Toll-like receptor 4
contributes to chronic itch, alloknesis, and spinal astrocyte activation in male
mice. Pain 2016;157:806e17.
32. Tsujino H, Kondo E, Fukuoka T, Dai Y, Tokunaga A, Miki K, et al. Activating
transcription factor 3 (ATF3) induction by axotomy in sensory and motoneu-
rons: a novel neuronal marker of nerve injury. Mol Cell Neurosci 2000;15:
170e82.
33. Tominaga M, Ogawa H, Takamori K. Histological characterization of cutaneous
nerve ﬁbers containing gastrin-releasing peptide in NC/Nga mice: an atopic
dermatitis model. J Invest Dermatol 2009;129:2901e5.
34. Tominaga M, Tengara S, Kamo A, Ogawa H, Takamori K. Psoralen-ultraviolet A
therapy alters epidermal Sema3A and NGF levels and modulates epidermal
innervation in atopic dermatitis. J Dermatol Sci 2009;55:40e6.
35. Tominaga M, Takamori K. Itch and nerve ﬁbers with special reference to atopic
dermatitis: therapeutic implications. J Dermatol 2014;41:205e12.
36. Sandor K, Helyes Z, Elekes K, Szolcsanyi J. Involvement of capsaicin-sensitive
afferents and the Transient Receptor Potential Vanilloid 1 Receptor in
xylene-induced nocifensive behaviour and inﬂammation in the mouse. Neu-
rosci Lett 2009;451:204e7.
37. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity:
update on toll-like receptors. Nat Immunol 2010;11:373e84.
38. Ransohoff RM, Brown MA. Innate immunity in the central nervous system.
J Clin Invest 2012;122:1164e71.
39. Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch
sensation in the spinal cord. Nature 2007;448:700e3.
40. Sun YG, Zhao ZQ, Meng XL, Yin J, Liu XY, Chen ZF. Cellular basis of itch
sensation. Science 2009;325:1531e4.
41. Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, et al. Genomic analysis
of reactive astrogliosis. J Neurosci 2012;32:6391e410.
42. Berard JL, Zarruk JG, Arbour N, Prat A, Yong VW, Jacques FH, et al. Lipocalin 2 is
a novel immune mediator of experimental autoimmune encephalomyelitis
pathogenesis and is modulated in multiple sclerosis. Glia 2012;60:1145e59.
43. Bi F, Huang C, Tong J, Qiu G, Huang B, Wu Q, et al. Reactive astrocytes secrete
lcn2 to promote neuron death. Proc Natl Acad Sci U S A 2013;110:4069e74.
44. Mucha M, Skrzypiec AE, Schiavon E, Attwood BK, Kucerova E, Pawlak R. Lip-
ocalin-2 controls neuronal excitability and anxiety by regulating dendritic
spine formation and maturation. Proc Natl Acad Sci U S A 2011;108:18436e41.
45. Kohro Y, Sakaguchi E, Tashima R, Tozaki-Saitoh H, Okano H, Inoue K, et al.
A new minimally-invasive method for microinjection into the mouse spinal
dorsal horn. Sci Rep 2015;5:14306.
46. Bourane S, Duan B, Koch SC, Dalet A, Britz O, Garcia-Campmany L, et al. Gate
control of mechanical itch by a subpopulation of spinal cord interneurons.
Science 2015;350:550e4.
47. Green D, Dong X. Supporting itch: a new role for astrocytes in chronic itch. Nat
Med 2015;21:841e2.
48. Ikoma A, Rukwied R, Stander S, Steinhoff M, Miyachi Y, Schmelz M. Neuronal
sensitization for histamine-induced itch in lesional skin of patients with atopic
dermatitis. Arch Dermatol 2003;139:1455e8.
